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1 F E B R U A R Y
Correspondence
Response of Treponema
pallidum Particle
Agglutination Test Titers to
Treatment of Syphilis
TO THE EDITOR—We recently published
on the serological response to treatment
of syphilis according to disease stage
and human immunodeﬁciency virus
(HIV) status [1]. In particular, we ana-
lyzed the course of the Venereal Dis-
ease Research Laboratory (VDRL) and a
speciﬁc immunoglobulin M capture
enzyme-linked immunosorbent assay
test (Pathozyme-IgM) in 264 patients.
Syphilis disease stage signiﬁcantly inﬂu-
enced treatment response whereas HIV
coinfection had an impact only in pa-
tients with primary syphilis.
Because not much is known about the
response of the widely used Treponema
pallidum particle agglutination (TPPA)
test titer to syphilis treatment, we also
analyzed the TPPA (Fujirebio, Tokyo,
Japan) results. A total of 212 patients
with an initially positive TPPA test (titer
≥1:80) were followed for at least 6
months after treatment and had at least
3 follow-up serologies.
On average, a reduction of 3.3 dilu-
tion steps in the TPPA titer was ob-
served during a mean follow-up
duration of 429 days (Table 1). However,
only 117 (55%) patients showed a con-
tinuous decrease of the TPPA titer, 30
(14%) maintained a constant titer, 4
(2%) had an increasing titer, and, most
interestingly, 61 (29%) patients demon-
strated a ≥2 dilution steps (≥4-fold)
ﬂuctuating titer—that is, the titer some
when during follow-up increased at least
4-fold with subsequent decrease to the
baseline or a lower titer. In 17 of these
patients the intermittent increase was
even ≥4 dilution steps. There was no
association with HIV status (P = .117).
None of the patients had clinical evi-
dence for reinfection or by VDRL serol-
ogy. We therefore conclude that a 4-fold
or greater increase of the TPPA titer
without other serological (eg, VDRL) or
clinical evidence does not necessarily in-
dicate syphilis reinfection.
A second interesting observation was
that 28 of 212 (13%) patients showed se-
roreversion of the TPPA (Table 1). Se-
roreversion was deﬁned as the last
follow-up serum being nonreactive. In
20 of these patients, >1 follow-up serum
(up to 5) was nonreactive. The median
time to seroreversion was only 227 days.
Half (14 of 28) of the patients had rela-
tively high initial titers of ≥1:1280. Se-
roreversion was associated with HIV
coinfection (P = .004), especially in sec-
ondary syphilis where 10 of 11 patients
were HIV positive. Although described
earlier [2–6], it is not widely known
among clinical and laboratory staff that
Table 1. Characteristics and Treponema pallidum Particle Agglutination Test Results of
212 Patients Who Were Followed for at Least 6 Months
Characteristic
All Patients
(N = 212)
TPPA
Seroreversion
(n = 28)
P
Valuea
Stage of syphilis .06b
Primary 74 16 (22)
Secondary 105 11 (10)
Tertiary 6 0
Latent 27 1 (4)
HIV serostatus .004b
Positive 95 20 (21)
Negative 117 8 (7)
TPPA baseline titer
Median titer 1:10240 1:960 <.001c
Interquartile range 1:1280–1:40960 1:160–1:3200
TPPA follow-up titers
Mean decrease (dilution steps) 3.3 5.0 .001d
Patients with ≥4-fold constant decrease 117 (55) NA
Patients with ≥4-fold fluctuating titer 61 (29) NA
Patients with constant titer (± 1 titer) 30 (14) NA
Patients with ≥4-fold increasing titer 4 (2) NA
Duration of follow-up, d, mean (range) 429 (175–729) 491 (223–711) .274d
Duration until seroreversion, d, mean (range) NA 227 (101–656)
No. of follow-up visits, mean (range) 4.6 (3–12) 4.8 (3–8) .139c
Data are presented as No. (%) unless otherwise specified.
Abbreviations: HIV, human immunodeficiency virus; NA, not applicable; TPPA, Treponema pallidum
particle agglutination.
a As compared with the subgroup without seroreversion.
b Fisher exact test.
c Exact Mann-Whitney test.
d t test.
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this may occur. It is generally believed
that the TPPA remains positive after
treatment. The overall rate of 21% HIV-
coinfected patients with TPPA serore-
version, for unknown reasons, is higher
than the previously reported rates of
5%–11.5% [2–5]. Additionally, we found
7% HIV-negative patients with TPPA
seroreversion. Only 2 previous studies
reported seroreversion among HIV-
negative patients with rates of 3%–13%
[2, 6]; other studies did not ﬁnd rever-
sion among HIV-negative persons [3–5].
In conclusion, a 4-fold or greater in-
crease of the TPPA titer does not neces-
sarily indicate reinfection or inadequate
therapy, and a negative TPPA titer does
not exclude previous syphilis infection.
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